Recent Quotes
My Watchlist
Indicators
Local Stocks
NewsOK Local Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Catalyst Pharm Inc (NQ: CPRX )

15.08 +0.02 (+0.13%)
Streaming Delayed Price Updated: 1:35 PM EDT, Jun 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Catalyst Pharm Inc

< Previous 1 2 3 4 5 6 Next >
A Closer Look at 7 Analyst Recommendations For Catalyst Pharmaceuticals
Via Benzinga
2 Incredible Growth Stocks to Buy Hand Over Fist Right Now
These two healthcare stocks may be deeply undervalued. 
Via The Motley Fool
Catalyst Pharmaceuticals Stock Clears Technical Benchmark With 83 RS Rating
On Tuesday, Catalyst Pharmaceuticals stock hit a key technical milestone, with its Relative Strength Rating climbing to 83 from 79. 
Via Investor's Business Daily
Decoding 8 Analyst Evaluations For Catalyst Pharmaceuticals
Via Benzinga
Catalyst's New CEO Has Big Ideas For The Small Biotech
Richard Daly is Catalyst Pharmaceuticals' second CEO, taking over for Patrick McEnany, who retired last year. 
Via Investor's Business Daily
CPRX Stock Earnings: Catalyst Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024
CPRX stock results show that Catalyst Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Decoding 7 Analyst Evaluations For Catalyst Pharmaceuticals
Via Benzinga
Assessing Catalyst Pharmaceuticals: Insights From 4 Financial Analysts
Via Benzinga
Earnings Preview For Catalyst Pharmaceuticals
Via Benzinga
Top 10% Biotech Catalyst Pharma Slips On Mixed First-Quarter
The company doubled Wall Street's earnings views, but sales came in short. 
Via Investor's Business Daily
3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch List
Don’t miss out on these three strong buy biotech stocks that are leaders to add to your portfolio for Q2 this year. 
Via InvestorPlace
7 Biotech Stocks Ready to Ride the Sector’s Resurgence
With investors seeking new opportunities with certain segments appearing stretched, biotech stocks offer a viable canvas. 
Via InvestorPlace
Madrigal Pharmaceuticals Stock Hits 80-Plus Relative Strength Rating Benchmark
On Monday, Madrigal Pharmaceuticals stock hit a key technical milestone, seeing its Relative Strength Rating jump to 83 from 69 a day ago. 
Via Investor's Business Daily
3 Sexy Small-Cap Stocks to Add Sizzle to Your Portfolio
While small-cap stocks can be incredibly risky, they also offer the potential for dramatic gains you won’t find with the big dogs. 
Via InvestorPlace
Amicus Therapeutics Stock Sees RS Rating Improve To 74
In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 69 to 74 on Tuesday. 
Via Investor's Business Daily
Why Catalyst Pharmaceuticals Stock Is Trading Lower
Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) shares are trading lower by 13% to $14.89 Friday morning. 
Via Benzinga
3 Biopharma Stocks You Don't Want to Miss in the New Bull Market
All three have exciting programs on the way. 
Via The Motley Fool
Top 3 Health Care Stocks You May Want To Dump In Q1
As of Feb. 29, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. 
Via Benzinga
Jim Cramer Likes This Bank 'Very, Very Much,' Says Stock Is Up 7% Over Past 6 Months
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Stanley Black & Decker, Inc. 
Via Benzinga
Next Big Thing: 3  Biotech Stocks to Watch for Groundbreaking Advances
With our improving economy, you need to invest in these top biotech stocks that are looking to strike gold this year. 
Via InvestorPlace
Topics Economy
Exposures Economy
3 Biotech Stocks You Can Buy and Hold for the Next Decade
These companies are still in the early innings of their growth potential. 
Via The Motley Fool
Forget Shiba Inu: This Stock is Poised for a Potential Bull Run in 2024
With multiple drugs on the market and revenue ramping up, the sky's the limit. 
Via The Motley Fool
3 Unstoppable S&P 600 Small-Cap Stocks to Buy in January
Small-cap stocks tend to outperform mid- and large-cap stocks over time and make for an important component of a balanced portfolio. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
Why Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Applied Therapeutics, Inc. 
Via Benzinga
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain. 
Via Investor's Business Daily
Franklin Covey Shares Fall After Q1 Results, Joins Theravance Biopharma, Voyager Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow Jones futures falling around 50 points on Friday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Amgen Stock Sees Relative Strength Rating Improve To 74
Amgen stock saw a positive improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 69 to 74. 
Via Investor's Business Daily
Cytokinetics Stock Jumps To Higher RS Level; Shoots Up On Heart Drug Study
On Thursday, Cytokinetics stock cleared a key performance benchmark, with its Relative Strength Rating jumping to 99 from 89 the day before. 
Via Investor's Business Daily
Ultragenyx Pharm Stock Hits 80-Plus Relative Strength Rating Benchmark
On Thursday, Ultragenyx Pharm stock received a positive adjustment to its Relative Strength (RS) Rating, from 77 to 81. 
Via Investor's Business Daily
Recursion Pharm Showing Market Leadership As Biotech Stocks Shoot Higher
On Tuesday, Recursion Pharm stock reached a key technical benchmark, seeing its Relative Strength Rating jump to 91 from 88 the day before. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.